- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00964327
TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains
18 maj 2011 uppdaterad av: Tibotec Pharmaceuticals, Ireland
A Phase IIa Open-label, Randomized Trial to Determine the Antiviral Activity in 60 HIV Positive Subjects With Multiple PI Resistant Strains, Receiving Either Control Treatment or a Daily Dose of 800, 1600, 2400 or 3600 mg TMC114 (Darunavir) for 13 Days Followed by a Single Dose on Day 14
The purpose of this study is to determine the antiviral activity, safety and tolerability of 14 days of different doses of TMC114 to treat HIV-1 positive patients whose condition is failing on a current treatment regimen that includes a protease inhibitor (PI) (a medication used to reduce the amount of HIV virus in the blood).To be considered for the study, patients must have a documented resistance to at least 2 of the current PIs.
Pharmacokinetics and pharmacodynamics of TMC114 will also be assessed.
Studieöversikt
Detaljerad beskrivning
This is a Phase lla open-label (all people involved know the identity of the treatment), randomized (study drug assigned by chance), controlled (the patients of the control group continue the failing regimen), dose-finding study to determine the antiviral activity, safety and tolerability of a 14-day treatment with TMC114 (a protease inhibitor) for treatment of human immunodeficiency virus type 1 (HIV-1) positive patients who are considered resistant to (failing to improve on) 2 or more protease inhibitors (PIs).
Sixty HIV-1 positive patients, who are resistant to multiple PIs as confirmed by specialized testing (virtual phenotyping) and who are currently failing to improve on a treatment regimen that contains a PI, will be randomly assigned to one of 5 treatment groups.
Those randomized to the control group will continue their current therapy (consisting of PIs and Nucleoside Reverse Transcriptase Inhibitor(s) (NRTIs)).
Those randomized to the TMC114 treatment groups will receive the study drug as a substitute for all the PIs in the current failing treatment regimen at the following dose levels: 400 or 800 mg twice a day, or 800 or 1200 mg three times a day for 13 days followed by a single dose on day 14.
The dose of the NRTIs (NRTIs are drugs that suppress replication of retroviruses) will remain unchanged until the end of the treatment period.
The trial will involve a screening period of maximum three weeks, a 7-day run-in period (the period of time before study start when no treatment is given), a 14-day treatment period, followed by a 6- week follow-up period.
The maximal trial duration will thus be twelve weeks.
Primary objective is to determine the antiviral activity of TMC114 as well as the pharmacokinetics (how the drug is absorbed in the body, distributed within the body and how it is removed from the body over time) and pharmacodynamics (the study of the action of effects a drug has on the body) will also be assessed over the 2 week period.Safety will be followed at regular intervals during treatment and follow-up period.
Safety assessments consist of regular lab assessments, ECG recording, vital signs, physical examination, body weight and Body Mass Index.
Observation of and interview for adverse events will be done daily during the first week of treatment, every second day during the 2nd week of treatment, and at week 1, 3 and 6 of the follow-up period.
In addition an Independent Data Monitoring Committee will evaluate the study data at regular intervals.
Patients will be randomly assigned to one of 5 treatment groups: 400 or 800 mg twice a day for 13 days followed by a single dose on day 14, or 800 or 1200 mg three times a day for 13 days followed by a single dose on day 14.
Patients randomized to the control group will continue their current therapy consisting of protease inhibitors (PIs) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
Studietyp
Interventionell
Inskrivning (Faktisk)
42
Fas
- Fas 2
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Patient has a documented HIV-1 infection with a viral load at screening visit above 2,000 HIV copies/ml
- Currently treated with a failing antiretroviral regimen consisting of NRTIs together with one or more PI(s)
- Has a resistance against at least 2 of the currently used PIs
- Patient agrees not to change the current therapy until end of run-in and agrees not to change NRTIs until the end of treatment period
- No current AIDS defining illnesses
Exclusion Criteria:
- NNRTI (non-nucleoside reverse transcriptase inhibitor) containing regimen, two weeks prior to screening
- Suspicion of alcohol abuse or drug abuse, leading to non-compliance
- History of significant drug allergy induced by PIs
- CD4 count < 50
- Life expectancy of less than 6 months
- Pregnant or breast feeding females
- Females of childbearing potential without use of a highly effective birth control method or not willing to continue practicing this birth control method for at least 14 days after the end of the treatment
- Received an investigational drug within 30 days prior to the trial drug administration
- Patients with clinically significant laboratory abnormalities.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
To determine the antiviral activity of TMC114.
Tidsram: Screening, days -7, -3, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 , 15, follow-up weeks 1, 3 and 6
|
Screening, days -7, -3, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 , 15, follow-up weeks 1, 3 and 6
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
nadir of viral load
Tidsram: Screening, days -7, -3, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 , 15, follow-up weeks 1, 3 and 6
|
Screening, days -7, -3, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 , 15, follow-up weeks 1, 3 and 6
|
Pharmacokinetics (PK) / Pharmacodynamics (PD): Plasma concentration of TMC114 and efficacy and safety data will be analyzed to find relationships between PK and PD.
Tidsram: 12 visits
|
12 visits
|
CD4 count
Tidsram: 7 visits
|
7 visits
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 augusti 2001
Primärt slutförande (Faktisk)
1 oktober 2003
Avslutad studie (Faktisk)
1 oktober 2003
Studieregistreringsdatum
Först inskickad
27 juli 2009
Först inskickad som uppfyllde QC-kriterierna
20 augusti 2009
Första postat (Uppskatta)
24 augusti 2009
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
19 maj 2011
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
18 maj 2011
Senast verifierad
1 april 2010
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- HIV-infektioner
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Proteashämmare
- HIV-proteashämmare
- Virala proteashämmare
- Darunavir
Andra studie-ID-nummer
- CR006718
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Boston Children's HospitalSterileCare Inc.Anmälan via inbjudanCentral Line komplikation | Central Line-associated Bloodstream Infection (CLABSI)Förenta staterna
Kliniska prövningar på TMC114
-
Janssen Research & Development, LLCAvslutad
-
Tibotec Pharmaceuticals, IrelandAvslutadHIV-infektionFörenta staterna, Australien, Frankrike, Storbritannien, Tyskland, Spanien, Belgien, Portugal, Kanada, Argentina, Brasilien, Österrike, Ungern
-
Tibotec Pharmaceuticals, IrelandAvslutad
-
Tibotec Pharmaceuticals, IrelandAvslutadHIV-infektionerFörenta staterna, Argentina
-
Janssen-Cilag International NVAvslutadHIV-infektioner | Humant immunbristvirus | Förvärvat immunbristsyndromvirus | AIDS-virusStorbritannien, Belgien, Tyskland, Spanien, Portugal, Israel, Danmark, Ryska Federationen, Österrike, Ungern, Schweiz
-
Tibotec Pharmaceuticals, IrelandAvslutadHIV-infektionFörenta staterna, Australien, Frankrike, Storbritannien, Belgien, Tyskland, Spanien, Argentina, Chile, Mexiko, Portugal, Malaysia, Panama, Sydafrika, Kanada, Nederländerna, Brasilien, Puerto Rico, Österrike, Ryska Federationen, T... och mer
-
Janssen Research & Development, LLCAvslutadHumant immunbristvirus (HIV)Förenta staterna, Spanien, Sydafrika
-
Tibotec Pharmaceuticals, IrelandAvslutadHIVStorbritannien, Tyskland, Danmark, Belgien, Österrike, Polen, Australien, Ryska Federationen